Therapeutic benefit of Ribociclib treatment for metastatic breast carcinoma – case presentation

Maria Militaru ¹, Maria Neag ¹, Andrea Otilia Onisim ², Florentina Claudia Militaru ^{1, 2 *}

¹ Toxicology and Clinical Pharmacology Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
² Medisprof Cancer Center, Cluj-Napoca, Romania
* Correspondence to: Florentina Claudia Militaru, Pharmacology, Toxicology and Clinical Pharmacology Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. E-mail: claudiamilitaru@yahoo.com

Abstract

Metastatic breast cancer is generally not curable with current treatments, though it is often treatable as a chronic disease. Currently, cyclin-dependent kinase 4/6 (CDK4/6) —palbociclib, ribociclib, and abemaciclib—play an important role in the treatment of advanced breast cancer. The purpose of this clinical case presentation is to demonstrate the therapeutic benefit of ribociclib therapy in a patient with de novo metastatic breast carcinoma.